Literature DB >> 17990293

F413C and A531V but not R894X myotonia congenita mutations cause defective endoplasmic reticulum export of the muscle-specific chloride channel CLC-1.

Hinni Papponen1, Marja Nissinen, Tuula Kaisto, Vilho V Myllylä, Raili Myllylä, Kalervo Metsikkö.   

Abstract

In northern Finland myotonia congenita is caused by three main mutations in the ClC-1 chloride channel. We studied the molecular basis of these mutations (1238T>G/F413C, 1592C>T/A531V, and 2680C>T/R894X). The mutated cDNAs were expressed either in L6 myotubes or in isolated rat myofibers using recombinant Semliki Forest virus. Experiments in L6 cells indicated that A531V and R894X proteins suffered from stability problems in these cells. Analysis in myofibers indicated that the A531V protein was totally retained in the endoplasmic reticulum (ER), whereas the export of the F413C protein was severely reduced. The C-terminal nonsense mutant (R894X), however, was normally transported to the Golgi elements in the myofibers. Defective export or reduced stability of the mutated proteins may thus be reasons for the myotonic symptoms.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 17990293     DOI: 10.1002/mus.20922

Source DB:  PubMed          Journal:  Muscle Nerve        ISSN: 0148-639X            Impact factor:   3.217


  14 in total

Review 1.  Channelopathies of skeletal muscle excitability.

Authors:  Stephen C Cannon
Journal:  Compr Physiol       Date:  2015-04       Impact factor: 9.090

2.  Nondystrophic myotonia: challenges and future directions.

Authors:  Jaya R Trivedi; Stephen C Cannon; Robert C Griggs
Journal:  Exp Neurol       Date:  2013-12-18       Impact factor: 5.330

Review 3.  Skeletal muscle channelopathies: new insights into the periodic paralyses and nondystrophic myotonias.

Authors:  Daniel Platt; Robert Griggs
Journal:  Curr Opin Neurol       Date:  2009-10       Impact factor: 5.710

Review 4.  Treatment of neuromuscular channelopathies: current concepts and future prospects.

Authors:  James C Cleland; Robert C Griggs
Journal:  Neurotherapeutics       Date:  2008-10       Impact factor: 7.620

Review 5.  The non-dystrophic myotonias: molecular pathogenesis, diagnosis and treatment.

Authors:  E Matthews; D Fialho; S V Tan; S L Venance; S C Cannon; D Sternberg; B Fontaine; A A Amato; R J Barohn; R C Griggs; M G Hanna
Journal:  Brain       Date:  2009-11-16       Impact factor: 13.501

6.  Dominantly inherited myotonia congenita resulting from a mutation that increases open probability of the muscle chloride channel CLC-1.

Authors:  David P Richman; Yawei Yu; Ting-Ting Lee; Pang-Yen Tseng; Wei-Ping Yu; Ricardo A Maselli; Chih-Yung Tang; Tsung-Yu Chen
Journal:  Neuromolecular Med       Date:  2012-07-12       Impact factor: 3.843

7.  The Cullin 4A/B-DDB1-Cereblon E3 Ubiquitin Ligase Complex Mediates the Degradation of CLC-1 Chloride Channels.

Authors:  Yi-An Chen; Yi-Jheng Peng; Meng-Chun Hu; Jing-Jia Huang; Yun-Chia Chien; June-Tai Wu; Tsung-Yu Chen; Chih-Yung Tang
Journal:  Sci Rep       Date:  2015-05-29       Impact factor: 4.379

Review 8.  ClC-1 chloride channels: state-of-the-art research and future challenges.

Authors:  Paola Imbrici; Concetta Altamura; Mauro Pessia; Renato Mantegazza; Jean-François Desaphy; Diana Conte Camerino
Journal:  Front Cell Neurosci       Date:  2015-04-27       Impact factor: 5.505

9.  ClC-1 mutations in myotonia congenita patients: insights into molecular gating mechanisms and genotype-phenotype correlation.

Authors:  P Imbrici; L Maggi; G F Mangiatordi; M M Dinardo; C Altamura; R Brugnoni; D Alberga; G Lauria Pinter; G Ricci; G Siciliano; R Micheli; G Annicchiarico; G Lattanzi; O Nicolotti; L Morandi; P Bernasconi; J-F Desaphy; R Mantegazza; D Conte Camerino
Journal:  J Physiol       Date:  2015-07-14       Impact factor: 5.182

10.  Myotonia congenita mutation enhances the degradation of human CLC-1 chloride channels.

Authors:  Ting-Ting Lee; Xiao-Dong Zhang; Chao-Chin Chuang; Jing-Jer Chen; Yi-An Chen; Shu-Ching Chen; Tsung-Yu Chen; Chih-Yung Tang
Journal:  PLoS One       Date:  2013-02-12       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.